Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly
assigned to receive either tacrolimus or cyclosporine microemulsion in combination with
mycophenolates. Patients will be followed including protocol biopsy at 1, 12, 36, 60 month
posttransplant, regular nuclein acid testing (NAT) for cytomegalovirus (CMV), Epstein-Barr
virus (EBV) and BK virus (BKV) in urine and blood.
The investigation is undertaken to clarify the reason for equal survival rates for patients
on cyclosporine and tacrolimus despite the lower rejection rate on tacrolimus.